Thanx. I appreciate and respect your opinions and comments. Not sure what an open label study is, but as far as catalysts go, it's anticipated that the company will be issuing an update before long, regarding the path they intend to take going forward. It's this update that I'm holding out for.
The company has sufficient cash going into 2017, I believe, so $$ won't be a problem any time soon.
TTPH's all time low is 6.62 and it tested and held a 7.20 range bottom so far, so the downside 'seems' minimal. Key word: seems.
Not to make a nuisance of myself pounding the table over a misguided or informed personal opinion/belief, but I think it deserving to reiterate a valid point/argument.
TTPH has $200M+ remaining working capital to rectify differences in recent IGNITE 2 P3 results.
This, on top of successful and commercially viable IGNITE 1 P3 results.
I strongly suggest a second/third look at TTPH as a very handsome potential gainer over the next 3 months.
(BTW and FWIW, latest analysts have targeted TTPH at $17-$19)
News 
Market Data 
Discover 
